The Impact of Remote Ischemic Preconditioning on Arterial Stiffness and Heart Rate Variability in Patients with Angina Pectoris

Naufal Zagidullin *, Elena Scherbakova, Yuliana Safina, Rustem Zulkarneev and Shamil Zagidullin

Department of Internal Diseases, Bashkir State Medical University, Ufa, 450000, Russia; alnushka555@mail.ru (E.S.); y.f.safina@mail.ru (Y.S.); zrustem@ufanet.ru (R.Z.); zshamil@inbox.ru (S.Z.)

* Correspondence: znaufal@mail.ru; Tel.: +7-347-293-08-85

Academic Editor: Lindsay Brown
Received: 26 March 2016; Accepted: 17 June 2016; Published: 23 June 2016

Abstract: Remote ischemic preconditioning (RIPC) is the set of ischemia episodes that protects against subsequent periods of prolonged ischemia through the cascade of adaptive responses; however, the mechanisms of RIPC are not entirely clear. Here, we aimed to study the impact of RIPC in patients with stable angina pectoris and compare it with healthy individuals with respect to arterial stiffness and heart rate variability. In the randomized, sham-controlled, crossover blind design study, a group of 30 coronary heart disease (CHD) patients (63.9 ± 1.6 years) with stable angina pectoris NYHA II-III and a control group of 20 healthy individuals (58.2 ± 2.49) were both randomly allocated for remote RIPC or sham RIPC. Arterial stiffness, pulse wave velocity (Spygmacor, Australia), and heart rate variability (HRV) were recorded before and after the procedure followed by the crossover examination. In the group of healthy individuals, RIPC showed virtually no impact on the cardiovascular parameters, while, in the CHD group, the systolic and central systolic blood pressure, central pulse pressure, and augmentation decreased, and total power of HRV improved. We conclude that ischemic preconditioning reduces not only systolic blood pressure, but also reduces central systolic blood pressure and improves arterial compliance and heart rate modulation reserve, which may be associated with the antianginal effect of preconditioning.

Keywords: RIPC; angina pectoris; arterial stiffness; heart rate variability

1. Introduction

More than 25 years have passed since initial research conducted by Reimer K.A. et al., (1986) [1] on the assessment in dogs of the positive effects of intermittent circumflex artery occlusion, prevented cumulative metabolic deficits and myocardial ischemic cell death. This procedure was referred to as “ischemic preconditioning” (IPC) when performed in supplying target organ arteries and remote IPC (RIPC) when provided away from the target organ, for example, on an upper or lower limb [2]. IPC has both immediate and long-term effects, the severity of which vary in different organs and have different molecular and clinical pathways [3,4]. Subsequent studies carried out in humans based on the principle of RIPC have shown that renal, cerebral, and intestinal ischemia also has a protective effect on the heart. Recently, the effect of remote and classical IP has been proven in large-scale studies on humans [5,6]. Meta-analysis in RIPC showed cardiorenal protection by reducing the incidence of myocardial infarction (both STEMI and nSTEMI) and showing less release of cardiac enzymes in patients undergoing elective percutaneous coronary interventions (PCI) [7–10]. Some larger trials are currently underway: the ERICp (The Effect of Remote Ischemic Preconditioning on Clinical Outcomes) PCI trial, evaluating RIPC in STEMI patients, the EURO-CRIPS (the EUROpean
and Chinese cardiac and renal Remote Ischemic Preconditioning Study trial, evaluating RIPC in the setting of PCI being performed for all indications apart from STEMI, and ERICCA (The Effect of Remote Ischemic Preconditioning on Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery), in patients with coronary artery bypass grafting. However, this effect was not present for primary endpoints in cardiovascular surgery [11], although the reduction of troponin release after coronary bypass grafting was clear [12,13].

In recent years, intensive studies on the mechanisms of RIPC in coronary heart disease (CHD) including gene and cellular levels have been conducted [14–16]. In patients with CHD, especially after myocardial infarction, the endothelial dysfunction is often revealed [17]. The data appeared supporting the positive impact of RIPC endothelial function based mostly on serum and tissue biomarkers [18]. Liang et al. [19] showed improvement of flow-mediated dilatation, activating a signal transducer and transcription-3 marker, and an increase in CD34+ endothelial progenitor cells found in arteries after 5 times each 4 min once daily 20 days long RIPC protocol. RIPC prevented also radial artery endothelial dysfunction induced by ischemia-reperfusion injury, probably mediated by cyclooxygenase-2 [20]. One of the leading mechanisms of RIPC in CHD seems to be neuronal signaling from the preconditioned extremity to the heart [21]. The afferent and efferent local and common neural pathways are involved in RIPC [4], because vagotomy and atropine abrogated of effects of the procedure [22,23]—so the autonomic nervous system status could be modified with RIPC, which, in turn, could be proved by the heart rate variability (HRV) test. Thus, on the one hand, the clinical efficacy of RIPC in a number of target organs was shown, and, on the other hand, the potential mechanistic pathways underlying RIPC (neural, humoral and systemic response) of IP are well investigated [24]. However, the precise clinical interactions between IP potential mechanisms and clinical RIPC efficacy are lacking. We hypothesized that RIPC could have an impact on arterial stiffness, pulse wave velocity, and HRV which might partly explain the positive impact of the procedure in coronary heart disease.

The objective was in the prospective, randomized, sham-controlled, crossover blind design study to investigate the impact of ischemic preconditioning in patients with coronary heart disease on arterial stiffness, oxygen saturation, pulse wave velocity, and heart rate variability.

2. Experimental Section

In the study, 30 patients with stable angina pectoris and 20 healthy individuals in a control group were investigated. No randomization was made between the groups and the participants were recruited in the groups independently. The study design is shown in Figure 1. Patients with CHD and those from the control group were equally investigated. All the participants signed an informed consent form. The following was examined: blood pressure (BP) by Korotkov, pulse oximetry (SpO₂), pulse wave velocity (PWV), and arterial stiffness by applanation tonometry (Sphygmacor, West Ryde, Australia). Ten-minute electrocardiography recorded in the supine position for the HRV analysis was performed before (Investigation 1) and immediately after (Investigation 2) remote RIPC. The first investigation was followed by a randomization with the help of a simple random number generator (at www.randomizer.org) for 2 groups with a probability of 1/2 for each choice to determine whether RIPC or sham RIPC (sRIPC) would be conducted first. RIPC was conducted by means of a three-time 5-minute’s forearm cycle cuff application with the inflation up to 50 mm Hg from the systolic blood pressure (BP) and two consecutive five-minute rests in between the cycles. Sham RIPC was conducted in a similar way, but the pressure in the cuff was pumped up to the diastolic BP (DBP) level for blinding purposes. From Day 2 to Day 7, the crossover examination (Investigation 3 and 4) was carried out, that is, the participants first applied with sRIPC underwent RIPC, while, in the second group, after RIPC the imitation was performed.
Exclusion criteria:

1. Significant arrhythmias (atrial fibrillation, atrial flutter, frequent premature atrial and ventricular beats, AV block, etc.),
2. Electric cardiotriggerer,
3. Obesity, body mass index >30 kg/m²,
4. Peripheral arterial disease,
5. Acute coronary syndrome and myocardial infarction within 3 months,
6. Severe heart failure.

Ethical clearance for the study was approved by Ethics Committee of Bashkir state Medical University (Ufa, Russian Federation) in conformity with ethical guidelines of the 1975 Declaration of Helsinki, and all the participants gave written informed consent. Data are presented as mean and mean error. Differences in the parameters dynamics were assessed by Student’s t-test for paired samples. A value of \( p < 0.05 \) was considered to be significant.

3. Results

A total of 30 patients with CHD and angina pectoris and 20 participants in the control group without CHD were investigated. Table 1 shows the basic cardiovascular characteristics of both groups. No significant changes in baseline characteristics was found between them; however, in the CHD group, the patients were older, mostly male, and shorter in height, and the arterial hypertension was more frequent—in 23 patients (76.7%) then in control group—4 patients (26.6%). In the CHD functional class NYHA II was defined in 26 patients (86.7%) and III—in 4 (13.3%).

In the control group, in accordance with randomization, 20 healthy participants were investigated in the RIPC-sRIPC \((n = 9)\) or sRIPC-RIPC \((n = 11)\) order, so that each one was studied four times. The summary investigation results after both examinations are shown in Table 2. The “Baseline” column presents the parameters before the test, the columns “after RIPC” and “after sRIPC” obviously present parameters after RIPC and sRIPC, and the “delta” column shows mean value differences before and after sRIPC and RIPC. No significant changes were observed before and after RIPC and sRIPC (all \( p > 0.05 \)).
was shown.

AP (augmentation pressure), %9.7

When compared with the control group, in the CHD group, the following features decreased:

- Significant difference between the two groups (p = 0.048). Pulse wave velocity in the control group did not change, whereas, in the CHD group, it was insignificantly downregulated. While the HF domain of HRV tended only to decrease in the control and the CHD group, the difference between them was significant (p = 0.006). Furthermore, total power (TP) decreased in the control group and increased in the CHD group, which resulted in a significant difference between the two groups (p = 0.007).

Similarly, in the CHD group, 14 patients were investigated in the RIPC–sRIPC, and 16 in the sRIPC–RIPC order. The results of the investigation of both orders are summarized in Table 3. After both sRIPC and RIPC, there was a significant decrease in the systolic BP (p = 0.029 with RIPC and p = 0.043 in sRIPC). Only after RIPC did the Pp (p = 0.024) and the augmentation pulse pressure AP (p = 0.031) decrease significantly, whereas, in the sham group, these parameters were not significant (p = 0.061 and p = 0.089, respectively). In both groups, there was a tendency for the heart rate to decrease, the low frequency (LF) domain of HRV increased, high frequency (HF) decreased, and the ratio of LF:HF shifted in favor of HF. Among all the HRV parameters in the RIPC group, the significant increase (p = 0.014) in the triangular index was shown.

At the next stage, we compared the change in cardiovascular parameters after RIPC in the control group and CHD groups in order to determine the impact of RIPC on the above-mentioned parameters (Table 4). When compared with the control group, in the CHD group, the following features decreased:

- SBP (p = 0.037), central SBP (p = 0.019), central pulse pressure Pp (p = 0.016), and augmentation pressure AP (p = 0.048). Pulse wave velocity in the control group did not change, whereas, in the CHD group, it was insignificantly downregulated. While the HF domain of HRV tended only to decrease in the control and the CHD group, the difference between them was significant (p = 0.006). Furthermore, total power (TP) decreased in the control group and increased in the CHD group, which resulted in a significant difference between the two groups (p = 0.007).

Table 1. Characteristics of participants in coronary heart disease (CHD) and control groups.

| Parameters          | CHD, n = 30 | Control, n = 20  |
|---------------------|-------------|-----------------|
| Age, (in years)     | 63.9 ± 1.6  | 58.2 ± 2.49     |
| Male (n)/Female (n) | 21/9        | 16/4            |
| Height, cm          | 169.7 ± 1.7 | 173.45 ± 1.5    |
| Weight, kg          | 81.4 ± 2.2  | 82.45 ± 3.4     |
| Body mass index, kg/m² | 28.27 ± 1.6 | 27.4 ± 1.1      |
| NYHA (n)            |             |                 |
| II                  | 26 (86.7%)  | 0               |
| III                 | 4 (13.3%)   | 0               |
| Arterial hypertension, n | 23 (76.7%) | 6 (30.0%)        |

Table 2. Remote ischemic preconditioning (RIPC) and sham RIPC (sRIPC) impact on cardiovascular parameters in control group (n = 20).

| Parameter                        | Sham Preconditioning | Ischemic Preconditioning |
|----------------------------------|-----------------------|---------------------------|
|                                  | Baseline             | After sRIPC | Delta       | Baseline             | After RIPC | Delta       |
| SBP, mm Hg                       | 118.6 ± 2.8          | 115.6 ± 3.7 | 3.0 ± 1.8 | 123.1 ± 2.6         | 120.1 ± 2.9 | 3.0 ± 2.8 |
| DBP, mm Hg                       | 74.6 ± 1.4           | 75.5 ± 1.8 | -0.9 ± 0.8 | 77.6 ± 2.2          | 77.1 ± 1.9 | 0.5 ± 2.2 |
| Central SBP, mm Hg               | 108.3 ± 3.5          | 106.5 ± 2.5 | 1.8 ± 1.9 | 111.2 ± 2.5         | 111.2 ± 2.5 | 0.0 ± 2.9 |
| Central DBP, mm Hg               | 75.9 ± 1.7           | 76.6 ± 1.8 | -2.7 ± 1.8 | 78.6 ± 1.8          | 77.5 ± 1.8 | 1.1 ± 2.1 |
| Pp, mm Hg                        | 33.9 ± 2.1           | 30.6 ± 3.1 | -3.3 ± 1.0 | 32.6 ± 2.2          | 32.7 ± 2.4 | -0.1 ± 1.5 |
| SpO₂, %                          | 97.9 ± 0.2           | 97.3 ± 0.28 | 0.6 ± 1.1 | 97.7 ± 0.3          | 97.7 ± 0.3 | 0.07 ± 1.4 |
| AP (augmentation pressure), %     | 9.7 ± 1.8            | 9.0 ± 2.3   | 0.7 ± 1.2 | 6.5 ± 1.3           | 8.4 ± 1.5   | -1.9 ± 1.4 |
| Pp amplification, %               | 133.2 ± 4.5          | 122.7 ± 4.1 | 0.5 ± 3.1 | 140.9 ± 4.7         | 133.7 ± 3.8 | 7.2 ± 3.1 |
| PWV, m/s                         | 7.22 ± 0.59          | 7.2 ± 0.49  | -0.02 ± 0.19 | 7.33 ± 0.63   | 7.35 ± 0.6   | -0.02 ± 0.29 |
| Heart rate, min                  | 68.1 ± 2.8           | 65.5 ± 2.7  | 2.6 ± 0.77 | 68.1 ± 2.8         | 65.5 ± 2.7  | 2.6 ± 0.87 |
| Triangular index                 | 6.85 ± 0.51          | 7.1 ± 0.51  | -0.25 ± 0.5 | 5.75 ± 0.28     | 6.4 ± 0.6   | -0.65 ± 0.6 |
| LF norm                          | 59.4 ± 5.1           | 66.6 ± 4.4  | -7.2 ± 4.2 | 58.9 ± 8.5        | 68.9 ± 8.4  | -10.0 ± 11.1 |
| HF norm                          | 40.6 ± 5.1           | 33.4 ± 4.4  | 7.2 ± 4.5 | 41.1 ± 8.5         | 31.0 ± 4.8  | 10.1 ± 10.5 |
| LF/HF ratio                      | 2.0 ± 0.39           | 3.0 ± 0.74  | -1.0 ± 0.7 | 1.43 ± 0.9        | 2.22 ± 0.9  | -0.79 ± 1.0 |
| TP                               | 753.1 ± 300.2        | 661.9 ± 151.6 | 91.2 ± 91.1 | 1096.3 ± 431.5 | 627.1 ± 238.5 | 469.2 ± 91.1 |

P.s.: p < 0.05 comparison (delta) of the parameter before and after RIPC/sRIPC.
autonomic nervous system heart rate control has also been proposed. Afferent and efferent sympathic and parasympathetic neural pathways in RIPC, the effect on the endothelium [25] by means of sympathetic and parasympathetic nervous systems and mechanisms of interaction of basic science and bedside knowledge on RIPC. RIPC effects are surely devoted to the mechanisms of both pre- and post-RIPC. The introduction of it into clinical practice.

Table 3. Changes in cardiovascular parameters after sRIPC/RIPC in CHD group (n = 30).

| Parameter                  | Sham Ischemic Preconditioning | Ischemic Preconditioning |
|----------------------------|-------------------------------|--------------------------|
|                            | Base                          | After sRIPC Δ            | Base | After RIPC Δ |
| SBP, mm Hg                 | 137.0 ± 3.3                   | 120.1 ± 3.2 *            | 134.7 ± 5.3 | 119.4 ± 4.0 * | 153.5 ± 3.5 |
| DBP, mm Hg                 | 84.7 ± 1.8                    | 77.7 ± 1.8               | 79.2 ± 2.7 | 75.2 ± 2.3 | 4.0 ± 2.8 |
| Central SBP, mm Hg         | 134.9 ± 3.7                   | 122.1 ± 3.8 *            | 132.9 ± 5.8 | 118.5 ± 4.0 * | 14.4 ± 3.9 |
| Central DBP, mm Hg         | 84.0 ± 1.9                    | 78.4 ± 2.0               | 78.7 ± 2.8 | 76.1 ± 2.3 | 2.6 ± 1.8 |
| PP, mm Hg                  | 50.7 ± 2.8                    | 44.1 ± 2.9               | 54.3 ± 4.2 | 42.25 ± 2.3 * | 12.0 ± 3.9 |
| SpO2, %                    | 97.2 ± 0.13                   | 97.93 ± 0.2              | 97.2 ± 0.4 | 97.3 ± 0.3 | −0.1 ± 0.3 |
| AP, %                      | 127.2 ± 1.8                   | 125.8 ± 2.7              | 131.4 ± 2.6 | 127.2 ± 1.8 * | 4.2 ± 2.1 |
| Pp, amplification, %       | 12.3 ± 1                      | 11.68 ± 1.2              | 12.3 ± 1.0 | 11.7 ± 1.2 | 0.5 ± 1.5 |
| PWV, m/sec                 | 5.5 ± 0.6                     | 6.0 ± 0.63               | 5.37 ± 0.8 | 4.95 ± 0.49 | 0.42 ± 0.53 |
| Heart rate, min            | 62.5 ± 2.2                    | 61.2 ± 2.4               | 68.6 ± 3.1 | 63.9 ± 3.0 | 4.7 ± 1.16 |
| Triangular index           | 5.78 ± 0.46                   | 6.7 ± 0.59               | 6.0 ± 0.46 | 9.0 ± 1.1 * | −3.0 ± 1.04 |
| LF norm                    | 26.4 ± 3.6                    | 31.8 ± 4.2               | 42.7 ± 5.5 | 48.1 ± 7.2 | −5.4 ± 2.2 |
| HF norm                    | 73.6 ± 3.6                    | 68.2 ± 4.2               | 57.3 ± 5.5 | 55.5 ± 7.2 | 1.8 ± 4.27 |
| LF:HF ratio                | 0.38 ± 0.07                   | 0.51 ± 0.12              | 0.75 ± 0.3 | 0.87 ± 0.25 | −0.12 ± 0.2 |
| TP                         | 2767.5 ± 1912.6              | 1736.1 ± 544.9           | 10774 ± 451.5 | 11561.1 ± 223.5 | −78.7 ± 84.2 |

P.s.: * p < 0.05 comparison (delta) of parameter before and after RIPC/sRIPC.

Table 4. Comparison of changes in the parameters in RIPC in the control and CHD groups.

| Parameters                  | ∆ RIPC, Control Group, n = 20 | ∆ RIPC, CHD Group, n = 30 | p |
|----------------------------|-------------------------------|----------------------------|---|
| SBP, mm Hg                 | 3.0 ± 2.8                      | 15.3 ± 3.5 *              | 0.028 |
| DBP, mm Hg                 | 0.5 ± 2.2                      | 4.0 ± 2.8                 | 0.19 |
| Central SBP, mm Hg         | 1.0 ± 2.9                      | 14.4 ± 3.9 *              | 0.009 |
| Central DBP, mm Hg         | 1.1 ± 2.1                      | 2.6 ± 1.8                 | 0.31 |
| Pp, mm Hg                  | −0.1 ± 1.5                     | 12.0 ± 3.9 **             | 0.008 |
| SpO2, %                    | 0.07 ± 1.4                     | −0.1 ± 0.3                | 0.26 |
| AP, %                      | −1.9 ± 1.4                     | 4.2 ± 2.1 *               | 0.041 |
| Pp, amplification, %       | 7.2 ± 3.1                      | 0.5 ± 1.5                 | 0.086 |
| PWV, m/sec                 | −0.02 ± 0.29                   | 0.42 ± 0.53               | 0.101 |
| HR, beat/min               | 2.6 ± 0.87                     | 4.7 ± 1.16                | 0.066 |
| Triangular index           | −0.65 ± 0.6                    | −3.0 ± 1.04               | 0.057 |
| LF norm                    | −10.0 ± 11.1                   | −5.4 ± 2.2                | 0.47 |
| HF norm                    | 10.1 ± 10.5                    | 1.8 ± 4.27                | 0.067 |
| LF:HF ratio                | −0.79 ± 1.0                    | −0.12 ± 0.2               | 0.076 |
| TP                         | 469.2 ± 91.1                   | −78.7 ± 84.2 **           | 0.006 |

Ps.: * p < 0.05 and ** p < 0.05 comparison (delta) of parameter before and after RIPC/sRIPC.

4. Discussion

Ischemic preconditioning is a non-invasive effective, inexpensive method of preventing or limiting ischemic injury of the heart, lungs, and kidneys. Over the past 15 years, much research has been devoted to the mechanisms of both pre- and post-RIPC. The introduction of it into clinical practice requires extensive studies and clinical trials until RIPC becomes standard therapy. Despite a large number of studies at the molecular and clinical levels, there is still not enough data about the precise mechanisms of interaction of basic science and bedside knowledge on RIPC. RIPC effects are surely mediated by endothelium [25] by means of sympathetic and parasympathetic nervous systems and vascular and tissue agents [18,26]. The procedure effect is partly explained by the endothelium dysfunction improvement [4,19–21], which accompanies CHD, which in turn is associated with the rise of central blood pressure and vascular wall stiffness [27,28]. Taking into account local and general afferent and efferent sympathetic and parasympathetic neural pathways in RIPC, the effect on the autonomic nervous system heart rate control has also been proposed.

In our study, the impact of RIPC, compared with sham RIPC, on BP, arterial stiffness, oxygen saturation, arterial stiffness, PWV, and HRV, in both CHD patients and healthy individuals, was investigated. In the RIPC studies, the number of cuff occlusion varied from 3 to 5, and chosen protocol (3 times × 5 min), was shown to be effective in some studies [29–31]. As a result, both RIPC and sRIPC
showed no impact on the investigated parameters in healthy participants, but, in the CHD group, RIPC improved endothelium compliance, reducing not only SBP, but also central SBP, central pulse pressure (Pp), and augmentation pressure (AP). The decrease of SBP and central SBP after sRIPC was quite a surprising finding and can be explained by venous vasodilatation, which might be caused by the pumping of the cuff in sRIPC to a diastolic level. Venous dilatation might restrict ventricle preload, which in turn may decrease the left ventricular ejection and both systolic parameters. RIPC stimulus are associated with arterial and coronary vasodilatation in animal [32] and human [33] models. According to recent studies, it has demonstrated a positive effect of RIPC on endothelial dysfunction, i.e., improving flow-mediated vasodilatation [34], increasing immunoreactivity of vasodilatative NO synthase [35], upregulating NO [36], increasing of endothelium progenitor cells [37] and vascular endothelial growth factor expression [38]. In our investigation, these pathways could explain the RIPC’s arterial vasodilatation, endothelial function improvement, and positive impact on arterial stiffness (decrease in AP and Pp). Taking into account the close relation between endothelial dysfunction and coronary ischemia, the decrease in arterial stiffness after RIPC shown above may have an antianginal effect on CHD patients. RIPC seems to have an impact also on electrocardiogram—Caru M. et al., in a recent study, showed QT shortening in healthy volunteers after a RIPC protocol [39]. In our study, in CHD patients, by analyzing HRV after RIPC, the total power parameter was at about the same level, whereas the control group showed a tendency to decline, and the difference between the groups in TP was evident. Moreover, when, in the control group, the autonomic disbalance between frequency domains (LF:HF ratio) tended to increase after RIPC, in the CHD group, it did not change. RIPC could provide this effect via local afferent nerves [40–42] and by vagus nerve modulation [22,23]. Total power is an important marker of autonomic heart rate modulation, and upregulation may be associated with better myocardial and coronary reserve.

There are some limitations to this study. The study was a single intervention showing short-term effects that may not be sustained and therefore may not improve clinical outcomes, which demands special investigation. It is also limited by the risk of unbalanced cofounders in the basic parameters in CHD and control groups (i.e., age, gender, height, and frequency of arterial hypertension). The small number of patients may also raise the risk of random error.

5. Conclusions

Thus, in the randomized crossover study with RIPC and RIPC imitation in patients with CHD and angina pectoris, the decreased systolic blood pressure, arterial stiffness, and heart rate variability improvement was shown, which may be associated with the antianginal effect of the procedure. These findings may help in the understanding of the mechanisms of RIPC in CHD patients for further use in clinical practice. However, larger studies to prove this hypothesis are needed.

Acknowledgments: This study was supported by the Grant of Russian President Foundation for Young PhDs (Zagidullin NS) MD-7395.2016.7 and the Russian Humanitarian State Foundation 15-36-01255.

Author Contributions: Naufal Zagidullin and Shamil Zagidullin conceived and designed the experiments, Elena Sherbakova and Yuliana Safina performed the experiments, Ruatem Zulkarneev analyzed the data, Naufal Zagidullin wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:

| Abbreviation | Definition |
|--------------|------------|
| AP           | pulse augmentation |
| CHD          | coronary heart disease |
| DBP          | diastolic blood pressure |
| HF           | high frequency low frequency (domain) |
| HR           | heart rate |
| HRV          | heart rate variability |
| RIPC         | ischemic preconditioning |
LF = low frequency (domain)
NYHA = New York Heart Association
PCI = percutaneous coronary interventions
Pp = pulse pressure
PWV = pulse wave velocity
sRIPC = sham ischemic preconditioning
SBP = systolic blood pressure
SpO2 = oxygen saturation
STEMI = ST-elevated myocardial infarction
nSTEMI = non ST-elevated myocardial infarction
TP = total power

References
1. Reimer, K.A.; Murry, C.E.; Yamasawa, I.; Hill, M.L.; Jennings, R.B. Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis. *Am. J. Physiol. Heart Circ. Physiol.* 1986, 251, H1306–H1315. [CrossRef] [PubMed]
2. Przyklenk, K.; Bauer, B.; Ovize, M.; Kloner, R.A.; Whittaker, P. Regional ischemic “preconditioning” protects remote virgin myocardium from subsequent sustained coronary occlusion. *Circulation* 1993, 87, 893–899. [CrossRef] [PubMed]
3. Sherbakova, E.S.; Zagidullin, N.S.; Plechev, V.V. Ischemic preconditioning in internal medicine and vascular surgery. *Med. Vestnik Bashkortostana.* 2014, 9, 118–123.
4. Pickard, J.M.; Betker, H.E.; Crimi, G.; Davidson, B.; Davidson, S.M.; Dutka, D.; Ferdinandy, P.; Ganske, R.; Garcia-Dorado, D.; Giricz, Z.; et al. Remote ischemic conditioning: From experimental observation to clinical application: Report from the 8th Biennial Hatter Cardiovascular Institute Workshop. *Basic Res. Cardiol.* 2015, 110, 453. [CrossRef] [PubMed]
5. Herrett, E.; Bhaskaran, K.; Timmis, A.; Denaxas, S.; Hemingway, H.; Smeeth, L. Association between clinical presentations before myocardial infarction and coronary mortality: A prospective population–based study using linked electronic records. *Eur. Heart J.* 2014, 35, 2363–2371. [CrossRef] [PubMed]
6. Schmidt, M.; Horváth-Puhó, É.; Pedersen, L.; Sørensen, H.T.; Betker, H.E. Time-dependent effect of preinfarction angina pectoris and intermittent claudication on mortality following myocardial infarction: A Danish nationwide cohort study. *Int. J. Cardiol.* 2015, 187, 462–469. [CrossRef] [PubMed]
7. Pei, H.; Wu, Y.; Wei, Y.; Yang, Y.; Teng, S.; Zhang, H. Remote Ischemic Preconditioning Reduces Perioperative Cardiac and Renal Events in Patients Undergoing Elective Coronary Intervention: A Meta—Analysis of 11 Randomized Trials. *PLoS ONE* 2014, 9, e115500. [CrossRef] [PubMed]
8. Yang, Y.; Lang, X.B.; Zhang, P.; Lv, R.; Wang, Y.F.; Chen, J.H. Remote ischemic preconditioning for prevention of acute kidney injury: A meta—analysis of randomized controlled trials. *Am. J. Kidney Dis.* 2014, 64, 574–583. [CrossRef] [PubMed]
9. Yellon, D.M.; Ackbarkhan, A.K.; Balgobin, V.; Bulluck, H.; Deelchand, A.; Dhuny, M.R.; Domah, N.; Gaoneadry, D.; Jagessur, R.K.; Joonas, N.; et al. Remote ischemic conditioning reduces myocardial infarct size in STEMI patients treated by thrombolysis. *J. Am. Coll. Cardiol.* 2015, 65, 2764–2765. [CrossRef] [PubMed]
10. Yamanaka, T.; Kawai, Y.; Miyoshi, T.; Mima, T.; Takagaki, K.; Tsukuda, S.; Kazatani, Y.; Nakamura, K.; Ito, H. Remote ischemic preconditioning reduces contrast—induced acute kidney injury in patients with ST—elevation myocardial infarction: A randomized controlled trial. *Int. J. Cardiol.* 2015, 178, 136–141. [CrossRef] [PubMed]
11. Healy, D.A.; Boyle, E.; McCartan, D.; Bourke, M.; Medani, M.; Ferguson, J.; Yagoub, H.; Bashar, K.; O'Donnell, M.; Newell, J. A MultiCenter Pilot Randomized Controlled Trial of Remote Ischemic Preconditioning in Major Vascular Surgery. *Vasc. Endovasc. Surg.* 2015, 49, 220–227. [CrossRef] [PubMed]
12. D’Ascenzo, F.; Moretti, C.; Omedè, P.; Cerrato, E.; Cavallero, E.; Er, F.; Presutti, D.G.; Colombo, F.; Crimi, G.; Conrotto, F. Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: A meta—analysis of randomised clinical trials. *Euro Intervention* 2014, 9, 1463–1471. [CrossRef] [PubMed]
13. Alreja, G.; Bugano, D.; Lotfi, A. Effect of remote ischemic preconditioning on myocardial and renal injury: Meta—analysis of randomized controlled trials. *J. Invasive Cardiol.* 2012, 24, 42–48. [PubMed]
14. Er, F.; Nia, A.M.; Dopp, H.; Hellmich, M.; Dahlem, K.M.; Caglayan, E.; Kubacki, T.; Benzing, T.; Erdmann, E.; Burst, V.; Gassanov, N. Randomized Pilot Ren Pro Trial (Renal Protection Trial). Ischemic Preconditioning for Prevention of Contrast Medium – Induced Nephropathy. *Circulation* 2012, 126, 296–303. [CrossRef] [PubMed]

15. Ghaemian, A.; Nouraei, S.; Abdollahian, F.; Naghshvar, F.; Giussani, D.A.; Nouraei, S.A. Remote ischemic preconditioning in percutaneous coronary revascularization: A double-blind randomized controlled clinical trial. *Asian Cardiovasc. Thorac. Ann.* 2012, 20, 548–554. [CrossRef] [PubMed]

16. Hausenloy, D.J.; Mwamure, P.K.; Venugopal, V.; Harris, J.; Barnard, M.; Grundy, E.; Ashley, E.; Vichare, S.; Di Salvo, C.; Kolvekar, S.; et al. Effect of remote ischemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: A randomised controlled trial. *Lancet* 2007, 370, 575–579. [CrossRef]

17. Hausenloy, D.J.; Mwamure, P.K.; Venugopal, V.; Harris, J.; Barnard, M.; Grundy, E.; Ashley, E.; Vichare, S.; Di Salvo, C.; Kolvekar, S.; et al. Effect of remote ischemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: A randomised controlled trial. *Lancet* 2007, 370, 575–579. [CrossRef]

18. Koch, S.; Della-Morte, D.; Dave, K.R.; Sacco, R.L.; Perez-Pinzon, M.A. Biomarkers for ischemic preconditioning: Finding the responders. *J. Cereb. Blood Flow Metab.* 2014, 34, 933–941. [CrossRef] [PubMed]

19. Karetova, D.; Korinek, J.; et al. Arterial Stiffening Contributes to Impairment of Cerebrovascular Reactivity in Patients With Coronary Artery Disease Without Carotid Stenosis. *Physiol. Res.* 2015, 64, 335–343. [PubMed]

20. Veerasamy, M.; Ford, G.A.; Neely, D.; Bagnall, A.; MacGowan, G.; Das, R.; Kunadian, V. Association of aging, arterial stiffness, and cardiovascular disease: A review. *Cardiol. Rev.* 2014, 22, 223–232. [CrossRef] [PubMed]

21. Veerasamy, M.; Ford, G.A.; Neely, D.; Bagnall, A.; MacGowan, G.; Das, R.; Kunadian, V. Association of aging, arterial stiffness, and cardiovascular disease: A review. *Cardiol. Rev.* 2014, 22, 223–232. [CrossRef] [PubMed]

22. Kharbanda, R.K.; Mortensen, U.M.; White, P.A.; Kristiansen, S.B.; Schmidt, M.R.; Hoschützky, J.A.; Vogel, M.; Sorensen, K.; Redington, A.N.; MacAllister, R. Transient limb ischemia induces remote ischemic preconditioning in vivo. *Circulation* 2002, 106, 2881–2883. [CrossRef] [PubMed]

23. Thielmann, M.; Kottenberg, E.; Kleinbongard, P.; Wendt, D.; Gedik, N.; Pasa, S.; Price, V.; Tsagakis, K.; Neuhäuser, M.; Peters, J.; et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: A single-centre randomised, doubleblind, controlled trial. *Lancet* 2013, 382, 597–604. [CrossRef]
31. Hoole, S.P.; Heck, P.M.; Sharples, L.; Khan, S.N.; Duehmke, R.; Denslem, C.G.; Clarke, S.C.; Shapiro, L.M.; Schofield, P.M.; O'Sullivan, M.; Dutka, D.P. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: A prospective, randomized control trial. *Circulation* 2009, 119, 820–827. [CrossRef] [PubMed]

32. Shimizu, M.; Konstantinov, I.E.; Kharbanda, R.K.; Cheung, M.H.; Redington, A.N. Effects of intermittent lower limb ischaemia on coronary blood flow and coronary resistance in pigs. *Acta Physiol. (Oxf.)* 2007, 190, 103–109. [CrossRef] [PubMed]

33. Enko, K.; Nakamura, K.; Yunoki, K.; Miyoshi, T.; Akagi, S.; Yoshida, M.; Toh, N.; Sangawa, M.; Nishii, N.; Nagase, S.; et al. Intermittent arm ischemia induces vasodilatation of the contralateral upper limb. *J. Physiol. Sci.* 2011, 61, 507–513. [CrossRef] [PubMed]

34. Loukogeorgakis, S.P.; Panagiotidou, A.T.; Broadhead, M.W.; Donald, A.; Deanfield, J.E.; MacAllister, R.J. Remote ischemic preconditioning provides early and late protection against endothelial ischemia–reperfusion injury in humans: Role of the autonomic nervous system. *J. Am. Coll. Cardiol.* 2005, 46, 450–456. [CrossRef] [PubMed]

35. Cho, S.; Park, E.-M.; Zhou, P.; Fryes, K.; Ross, M.E.; Iadecola, C. Obligatory role of inducible nitric oxide synthase in ischemic preconditioning. *J. Cereb. Blood Flow Metab.* 2005, 25, 493–501. [CrossRef] [PubMed]

36. Chen, H.; Xing, B.; Liu, X.; Zhan, B.; Zhou, J.; Zhu, H.; Chen, Z. Ischemic postconditioning inhibits apoptosis after renal ischemia/reperfusion injury in rat. *Transpl. Int.* 2008, 21, 364–371. [CrossRef] [PubMed]

37. Ii, M.; Nishimura, H.; Iwakura, A.; Wecker, A.; Eaton, E.; Asahara, T.; Losordo, D.W. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via “imported” nitric oxide synthase activity. *Circulation* 2005, 111, 1114–1120. [CrossRef] [PubMed]

38. Kawata, H.; Yoshida, K.; Kawamoto, A.; Kurioka, H.; Takase, E.; Sasaki, Y.; Hatanaka, K.; Kobayashi, M.; Ueyama, T.; Hashimoto, T.; Dohi, K. Ischemic preconditioning upregulates vascular endothelial growth factor mRNA expression and neovascularization via nuclear translocation of protein kinase C epsilon in the rat ischemic myocardium. *Circ. Res.* 2001, 88, 696–704. [CrossRef] [PubMed]

39. Caru, M.; Lalonde, F.; Gravel, H.; Daigle, C.; Tournoux, F.; Jacquemet, V.; Curnier, D. Remote preconditioning shortens QT intervals during exercise in healthy subjects. *Eur. J. Sport Sci.* 2016, 8, 1–9. [CrossRef] [PubMed]

40. Gross, E.R.; Hsu, A.K.; Urban, T.J.; Mochly-Rosen, D.; Gross, G.J. Nociceptive–induced myocardial remote conditioning is mediated by neuronal gamma protein kinase C. *Basic Res. Cardiol.* 2013, 108, 381. [CrossRef] [PubMed]

41. Steensrud, T.; Li, J.; Dai, X.; Manlhiot, C.; Kharbanda, R.K.; Tropak, M.; Redington, A. Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra–arterial adenosine. *Am. J. Physiol. Heart Circ. Physiol.* 2010, 299, H1598–H1603. [CrossRef] [PubMed]

42. Merlocco, A.C.; Redington, K.L.; Disenhous, T.; Strantzis, S.C.; Gladstone, R.; Wei, C.; Tropak, M.B.; Manlhiot, C.; Li, J.; Redington, A.N. Transcutaneous electrical nerve stimulation as a novel method of remote preconditioning: in vitro validation in an animal model and first human observations. *Basic Res. Cardiol.* 2014, 109, 406. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).